<DOC>
	<DOCNO>NCT00867516</DOCNO>
	<brief_summary>The purpose study determine safety efficacy ALD518 three different dos patient adequate response methotrexate .</brief_summary>
	<brief_title>Safety , Efficacy Pharmacokinetics Study ALD518 Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description>This phase II , parallel-group , double-blind , randomize , placebo-controlled study ALD518 patient active RA inadequate response methotrexate . Enrolled patient screen within 4-week period ( Day -35 -7 ) . within 12-day period ( Day-14 -3 ) initial dose Day 1 patient randomize one follow four treatment group : Group A : 2x ALD518 80 mg Group B : 2x ALD518 160 mg Group C : 2x ALD518 320 mg Group D : 2x placebo In treatment group patient continue take stable dose methotrexate . There total 11 visit . The total duration patient study participation approximately 16 week ( exclude screen period ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Active Rheumatoid Arthritis least 16 week duration Have Creactive protein ( CRP ) ≥ 10mg/L Have stable dose methotrexate ( ≥ 10mg/week ) least 3 month Arthritis onset prior 16 year old Received biologic therapy previous 12 month A history currently active tuberculosis Any clinically significant concurrent medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>